3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Breast Neoplasms
22
Colorectal Neoplasms
14
Ovarian Neoplasms
12
Lung Neoplasms
10
Neoplasm Metastasis
9
Stomach Neoplasms
8
Neoplasms
8
Nasopharyngeal Carcinoma
8
Leukemia, Myeloid, Acute
7
Triple Negative Breast Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Rectal Neoplasms
6
Fallopian Tube Neoplasms
6
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Esophageal Squamous Cell Carcinoma
5
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Leukemia
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Pancreatic Neoplasms
3
Neoplasms by Site
3
Lymphoma, Large B-Cell, Diffuse
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Multiple Myeloma
2
Interventions
Rituximab
14
pirtobrutinib
6
ibrutinib
4
Vincristine
4
Doxorubicin
4
Prednisone
3
Cytarabine
3
Cyclophosphamide
3
zanubrutinib
2
acalabrutinib
2
Methotrexate
2
Etoposide
2
Bendamustine Hydrochloride
2
venetoclax
1
tositumomab I-131
1
idelalisib
1
ibritumomab tiuxetan
1
etoposide phosphate
1
entecavir
1
cirmtuzumab
1
axicabtagene ciloleucel
1
VAP-cyclo protocol
1
Tenofovir
1
Radiotherapy
1
Melphalan
1
Ifosfamide
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell
×
Drug Therapy
×
Clear all
NCT03570892
2026-05-14
BELINDA
Novartis
Phase 3
Completed
330 enrolled
10 charts